09/08/17 First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. Journal of Immunotherapy. October 2017
09/08/17 A Phase 2 Study of CMB305 and Atezolizumab in NY-ESO-1+ Soft Tissue Sarcoma: Interim Analysis of Immunogenicity, Tumor Control and Survival. European Society of Medical Oncology (ESMO) 2017 Congress. Abstract # 1480PD. View Poster
06/05/17 Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma. American Society of Clinical Oncology (ASCO) Annual Meeting 2017. Abstract #7537. View Poster.
06/05/17 The Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients. American Society of Clinical Oncology (ASCO) Annual Meeting 2017. Abstract #3090. View Poster.
06/02/17 Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS). American Society of Clinical Oncology (ASCO) Annual Meeting 2017. Abstract #11006. View Presentation
04/05/17 Large established B16 tumors in mice are eradicated by ZVex® (dendritic cell-targeting lentiviral vector) and G100 (TLR4 agonist) combination immunotherapy through increasing tumor-infiltrating effector T cells and inducing antigen spreading. American Association for Cancer Research Annual Meeting 2017. Abstract #5673. View Poster.
04/05/17 04/05/2017 ZVex® lentiviral vector strongly activates pro-inflammatory, antigen processing, and anti-viral defense response pathways in monocyte-derived dendritic cells. American Association for Cancer Research Annual Meeting 2017. Abstract #5092. View Poster.
12/05/16 Intratumoral G100 Rescues Radiation-Induced T Cell Depletion and Has Synergistic Anti-Tumor Effect with Local Irradiation in A20 Lymphoma. Abstract #4166. American Society of Hematology (ASH) Annual Meeting 2016. View Poster.
11/11/16 Heterologous boosts with an adenoviral vector following a dendritic cell-tropic ZVex® prime generates robust antigen-specific T cell responses and enhanced anti-tumor protection. Society for Immunotherapy of Cancer (SITC) Conference Poster 354. The 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Conference. View Poster.
11/11/16 Multi-genome reassortant dendritic cell-tropic vector platform (ZVex®) allows flexible co-expression of multiple antigens and immune modulators for optimal induction of anti-tumor CD8+ T cell responses. Poster 195. The 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Conference. View Poster.
